TELA Bio, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Performance and Operational Evolution Achieved 16% full-year revenue growth and record fourth-quarter results despite undergoing a fundamental rebuild of the commercial organization. Attributed performance to strong European business adoption and continued momentum in IHR, LPR, and LiquiFix product lines. Implemented a 'deep and narrow' geographic strategy, shifting from wide distribution to concentrated density in high-volume institution ...